Navigation Links
ULURU Inc. Reports Third Quarter 2011 Financial Results
Date:11/15/2011

ased compensation, for the third quarter of 2010.  The decrease of approximately $63,000 in research and development expenses was primarily due to lower costs for regulatory fees of $42,000 and share-based compensation of $15,000.

Research and development expenses for the nine months ended September 30, 2011 were $749,000, including $52,000 in share-based compensation, compared to $949,000, including $104,000 in share-based compensation, for the nine months ended September 30, 2010.  The decrease of approximately $200,000 in research and development expenses was primarily due to lower costs for regulatory fees of $133,000, clinical testing costs of $43,000 and scientific compensation costs of $19,000.

Selling, General and Administrative

Selling, general and administrative expenses for the third quarter of 2011 were $566,000, including $25,000 in share-based compensation, compared to $666,000, including $26,000 in share-based compensation, for the third quarter of 2010.  The decrease of approximately $100,000 in selling, general and administrative expenses was primarily due to lower costs for sales & marketing of $135,000 as a result of lower head count, reduced share-based compensation, and decreased marketing expenses.  These expense decreases were partially offset by an increase in shareholder expenses relating to investor relations consulting of $61,000.

Selling, general and administrative expenses for the nine months ended September 30, 2011 were $1.8 million, including $77,000 in share-based compensation, compared to $2.4 million, including $195,000 in share-based compensation, for the nine months ended September 30, 2010.  The decrease of approximately $626,000 in selling, general and administrative expenses was primarily due to lower costs for compensation of $162,000 as a result of lower head count and reduced share-based compensation, sales & marketing costs of $284,000, legal costs relatin
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ... very important aspects in today,s growth in ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 /PRNewswire/ ... HTWR ), a leading innovator of less ... the treatment of advanced heart failure, today announced ... of 2013 will be approximately $53 million, bringing ... "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic ... LLC ("GMH"), announced today that it acquired Progressive Home Medical ... on January 7, 2014. The terms of the acquisition were ... durable medical equipment ("DME") company providing a wide range of ... Pennsylvania and Pittsburgh ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Bedford Laboratories™, a division of Ben Venue Laboratories, ... Topotecan Hydrochloride for Injection, 4 mg (base)/vial to ... the reference listed drug Hycamtin ® (topotecan ... Injection is indicated for the treatment of metastic ...
... Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2011 on Wednesday, April 27, 2011, after the close of ... will host a conference call to review the results beginning ... The press release and a live audio-only ...
Cached Medicine Technology:Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:4/14/2014)... moderate to severe obstructive sleep apnea is independently associated ... , Results of the 20-year follow-up study show that ... four times more likely to die (hazard ratio = ... stroke (HR = 3.7), three times more likely to ... more likely to develop cancer. Results were adjusted for ...
(Date:4/14/2014)... April 14, 2014 Popular web information on ... to read and doesn,t address the appropriate risks to ... Medical Center gastroenterologists suggests. , In a review of ... education materials for colorectal cancer screening were written beyond ... sites failed to address key risks, as well as ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... still more evidence that antibiotics can contribute to ... the journal Antimicrobial Agents and Chemotherapy ... weight and had significant changes in their gut ... Raoult, of Aix-Marseille University, Marseille, France, followed 48 ... and hydroxychloroquine for Q fever, and 34 control ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Long-term antibiotic treatment for Q fever causes weight gain 2Health News:Low birth weight, less breastfeeding create later health risks 2
... foods in schools from September onwards - confectionery, crisps ... School Food trust. ,The trust, which was ... standards on food provided in schools – that includes ... to Dame Suzi Leather, the trust's chairwoman, New food ...
... was suffering from a crippling mosquito-borne virus disease the Chikungunya ... around this area//. The World Health Organization (WHO) said ... the Indian Ocean region. ,This disease has no ... the Reunion, Mauritius and Seychelles since January. The disease was ...
... said that mammograms were able to detect non progressive ... previous studies// show that 54% of the mammograms detect ... is about 1% only. But the present study is ... Sophia Zackrisson, a radiologist from the Epidemiological Research Group, ...
... Research Center of the Medical College of Wisconsin in Milwaukee found ... with the lowest BMI are at greatest risk of death from ... drivers risk of dying in a car crash. On the ... ,Researchers also found that obesity in women does not ...
... claimed that they have developed a vaccine against two ... question can easily kill humans and could potentially be ... viruses is that Hendra virus emerged in 1994, killing ... in Brisbane. Thereafter the trainer of Vo Rogue, died ...
... have been urged to produce more antibiotics by ... federal legislation// is being encouraged to provide drug ... ,Combating the drug-resistant microbes should deserve the utmost ... anti-biotics have so far been developed to treat ...
Cached Medicine News:Health News:Threat from Chikungunya, No Longer a Fear 2Health News:Mammograms Detect Non Progressive Cancer 2
... easy, breezy, beautiful image to its eyewear ... of stylish colors, trendy shapes, spring hinges, ... to target the broad demographics of the ... fashionable frames. The Cover Girl Eyewear collection ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... The license agreement between Brook Brothers ... 1993. Characterized by lightweight materials and ... collections reflect the unique features of ... A product with classic style and ...
... debuted in 1937 with the Aviator style ... to Luxottica Group's brand portfolio in 1999. ... celebrities since day one, Ray-Bans styles are ... best-selling sunglasses in the world. Characterized by ...
Medicine Products: